Ascentage Pharma Grants 3.66M RSUs & 690K Share Options
Ascentage Pharma Group International announced the grant of 3,664,428 Restricted Share Units (RSUs) under its 2021 and 2022 RSU Schemes to 704 selected persons, including employees, directors, and a service provider. Additionally, the company granted 690,045 Share Options under its Post IPO Share Option Scheme to 30 grantees, including directors and employees. These grants aim to incentivize and retain key talent, rewarding their contributions and aligning their interests with the company's long-term growth. The RSUs and Options represent approximately 0.98% and 0.18% of the company's total issued share capital, respectively.
Key Highlights
- Granted 3,664,428 RSUs to 704 employees, directors, and a service provider.
- Granted 690,045 Share Options to 30 employees and directors.
- 2021 RSU Awards represent approximately 0.12% of issued share capital.
- 2022 RSU Awards represent approximately 0.86% of issued share capital.
- Share Options represent approximately 0.18% of issued share capital.
- Option exercise price set at HK$33.62 per Share.
- Vesting periods for awards and options vary, some immediate, some multi-year.
- Grants aim to incentivize and retain key talent for long-term growth.
Price Impact
More from AAPG
Ascentage Pharma Presents Positive Clinical Data for Olverembatinib & Lisaftoclax
Ascentage Pharma Presents Alrizomadlin & Olverembatinib Data at ASCO 2026
Ascentage Pharma's Olverembatinib Combo Shows Promising Ph Ib Results